What is Dian Diagnostics Group Co.,Ltd.'s (300244.SZ) StockRank?

MoatMap's StockRank for Dian Diagnostics Group Co.,Ltd. (300244.SZ) is 78/100, with a Buy signal. This is a composite score combining Quality (58), Value (49), and Momentum (58) factor ranks across MoatMap's 20,000+ stock universe.

Does Dian Diagnostics Group Co.,Ltd. have an economic moat?

Dian Diagnostics Group Co.,Ltd. (300244.SZ) has a Quality factor score of 58/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Dian Diagnostics Group Co.,Ltd. a buy, hold, or sell?

MoatMap's current signal for Dian Diagnostics Group Co.,Ltd. (300244.SZ) is Buy, based on a StockRank of 78/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Dian Diagnostics Group Co.,Ltd. in?

Dian Diagnostics Group Co.,Ltd. (300244.SZ) operates in the Healthcare sector, specifically the Diagnostics & Research industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300244.SZ

BUYREMOVE

Dian Diagnostics Group Co.,Ltd. · Healthcare · China · $1.6B · Avg Vol: $87M/d

StockRank

P/E (TTM)

89.5x

ROE

2.8%

D/E

0.3x

Dividend %

1.8%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Dian Diagnostics faces ongoing headwinds from post-COVID volume normalization and government-led centralized procurement pricing pressures in China.

COMPANY DESCRIPTION

Dian Diagnostics Group Co., Ltd. is a leading provider of independent clinical laboratory services and diagnostic product distribution in China. The company operates a comprehensive nationwide network of medical laboratories, offering over 3,000 diagnostic test items to hospitals and clinics. Its vertically integrated business model, combining diagnostic services with instrument sales, establishes a robust competitive moat through scale and cost efficiencies.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	3.0B	2.0B	1.8B	1.5B	-20.7%
EPS	0.34	0.07	-0.09	0.01	-68.5%
Shares	627M	627M	625M	625M	-0.3%
Debt	889M	620M	528M	392M	-23.9%
Equity	1.1B	1.1B	970M	952M	-4.7%
Op CF	242M	284M	178M	300M	7.4%
Inv CF	-158M	-101M	-79M	-48M	—
Fin CF	211M	-360M	-271M	-205M	—

PRICE (1M)-13.1%

SMA 50SMA 200

$2.71

RSI (14)

54.2

52W High

$4.92

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

4.0%54.1

ROE

2.8%50.2

GP/Assets

20.0%46.6

Op. Margin

8.7%63.2

FCF/Assets

11.5%90.0

Piotroski

—83.4

Int. Cover

2.6x47.9

D/E Ratio

0.29x44.6

Current Ratio

2.73x49.5

Value

P/E (TTM)

89.5x10.5

EV/EBITDA

16.4x24.4

P/FCF

45.2x88.4

P/B

1.8x59.7

P/S

1.2x81.0

Div Yield

1.8%46.7

Momentum

52W High %

55%30.8

RS 6M

11%84.0

SMA 50/200

1.01x63.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—88.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.6B

P/E (Forward)

28.7x

Gross Margin

28.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300244.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300244.SZ	Dian Diagnostics Group Co.,Ltd.(you)	$1.6B	78	BUY
6127.HK	Joinn Laboratories(China)Co.,Ltd.	$1.7B	77	BUY
300685.SZ	Amoy Diagnostics Co., Ltd.	$1.2B	80	BUY
603882.SS	Guangzhou Kingmed Diagnostics Group Co., Ltd.	$1.8B	67	BUY
300406.SZ	Beijing Strong Biotechnologies,Inc.	$1.0B	86	STRONG BUY
300676.SZ	BGI Genomics Co., Ltd.	$2.3B	37	HOLD
3347.HK	Hangzhou Tigermed Consulting Co., Ltd	$3.4B	41	HOLD
9960.HK	Kindstar Globalgene Technology, Inc.	$139M	70	BUY
300463.SZ	Maccura Biotechnology Co.Ltd	$845M	33	SELL
2427.HK	Guanze Medical Information Industry (Holding) Co., Ltd.	$526M	42	HOLD

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

Dian Diagnostics Group Co.,Ltd. (300244.SZ) — Stock Score Summary

Dian Diagnostics Group Co.,Ltd. (300244.SZ) has a MoatMap StockRank of 78/100 based on Quality (58/100), Value (49/100), and Momentum (58/100) factor scores. The current signal is BUY. Dian Diagnostics faces ongoing headwinds from post-COVID volume normalization and government-led centralized procurement pricing pressures in China.

Key Financial Metrics

Price	$2.71
Market Cap	$1.6B
P/E (TTM)	89.48
P/E (Forward)	28.69
Price/Book	1.76
Return on Equity	2.8%
Return on Invested Capital	4.0%
Debt/Equity	28.57
Gross Margin	28.8%
Operating Margin	8.7%
Revenue Growth	-5.0%
Dividend Yield	1.8%
Free Cash Flow	$36M

Dian Diagnostics Group Co.,Ltd. operates in the Diagnostics & Research industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Dian Diagnostics Group Co.,Ltd.’s (300244.SZ) StockRank?: MoatMap’s StockRank for Dian Diagnostics Group Co.,Ltd. (300244.SZ) is 78/100, with a Buy signal. It is a composite of Quality (58), Value (49), and Momentum (58) factor ranks across MoatMap’s 20,000+ stock universe.
Does Dian Diagnostics Group Co.,Ltd. have an economic moat?: Dian Diagnostics Group Co.,Ltd. (300244.SZ) has a Quality factor score of 58/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Dian Diagnostics Group Co.,Ltd. a buy, hold, or sell?: MoatMap’s current signal for Dian Diagnostics Group Co.,Ltd. (300244.SZ) is Buy, based on a StockRank of 78/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Dian Diagnostics Group Co.,Ltd. in?: Dian Diagnostics Group Co.,Ltd. (300244.SZ) operates in the Healthcare sector, specifically the Diagnostics & Research industry (China).